REPRISE III: Lotus and CoreValve Compared in High-Risk or Inoperable Patients

REPRISE III: Lotus and CoreValve Compared in High-Risk or Inoperable PatientsThe efficacy of transcatheter aortic valve replacement (TAVR) has been well-established. However, its limitations include suboptimal deployment and paravalvular leak. The Lotus system is a fully repositionable and retrievable device with controlled mechanical expansion. It features an adaptive seal to minimize paravalvular leak, it does not require early pacing during deployment, and, given its early functioning, the procedure is very stable, hemodynamically speaking.

 

This was a prospective noninferiority multicenter (United States, Canada, Germany, France, Australia, and Netherlands) study that randomized patients 2:1 to Lotus vs. CoreValve. Subjects had severe aortic stenosis, and presented high surgical risk or were inoperable.

 

The primary safety endpoint was a composite of death, stroke, major bleeding, renal insufficiency, and major vascular complications at 30 days. The primary efficacy endpoint was a composite of death, disabling stroke, and moderate or greater paravalvular leak at 1 year.

 

The study included 912 pacientes (CoreValve: 305; Lotus: 607) in 55 centers in the aforementioned countries, between 2014 and 2015.

 

The Lotus valve was noninferior as regards the primary safety endpoint at 30 days (Lotus, 19%, vs. CoreValve, 16%; p = 0.001 for noninferiority). Lotus was associated with a higher need for new pacemaker implantation (29.1 vs. 15.8; p < 0.001).

 

At 1 year, the curves for the primary safety endpoint were yuxtaposed (Lotus, 30.7%, vs. CoreValve, 30.2%; p = 0,83).

 

The Lotus device was also noninferior for the primary efficacy endpoint (Lotus, 16.7%, vs. CoreValve, 29%; p < 0.001 for noninferiority).

 

Both valves presented similar mortality rates (CoreValve, 13.7%, vs. Lotus, 11.9%; p = 0.48). However, CoreValve presented a higher rate of moderate to greater paravalvular leak (11.1% vs. 2.0%; p < 0.001) and a higher rate of disabling stroke (CoreValve, 7.3%, vs. Lotus, 3.6%; p = 0.02).

 

Conclusion

The Lotus valve turned out to be safe and effective when compared to the self-expanding device commercially available at the time of this study, CoreValve.

 

Dr. Ted Feldman
Dr. Ted Feldman

Original title: A Prospective, Randomised Investigation of a Novel Transcatheter Aortic Valve Implantation System: The REPRISE III Trial.

Presenter: Ted E. Feldman.

 

 

FeldmanTed


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...